News |
Investors
CONTACT US

Rafael Holdings

home Navigation
  • Leadership
    • Board of Directors
    • Executive Management
  • Rafael Pharmaceuticals
  • Rafael Pharmaceuticals
  • Real Estate Holdings
  • Lipomedix Pharmaceuticals
  • Leadership
    • Board of Directors
    • Executive Management
Investors

Investors

 
 
Rafael Holdings and Rafael Pharmaceuticals have announced a planned merger to create an integrated pharmaceutical company developing novel cancer therapies. The merged company would adopt the Rafael Pharmaceuticals, Inc. name and would include Rafael Holdings' interests in LipoMedix Pharmaceuticals Ltd. and the Barer Institute, a wholly-owned subsidiary developing a pipeline of compounds focused on the regulation of cancer metabolism. 
 

Recent News

  • Real Estate Holdings
  • Rafael Pharmaceuticals
  • Lipomedix Pharmaceuticals
  • Leadership
  • Press Releases
  • News Coverage
  • Investors
  • Contact Us
  • Privacy Policy
  • Disclaimer

Copyright © Rafael Holdings, Inc. All rights reserved


Privacy
Resize Viewer - Reduce Resize Viewer - Expand Close window